| 本文已被：浏览 200次 下载 47次 |
码上扫一扫！ |
| 2022年全球和中国胰腺癌发病及死亡分析 |
| 易丽夏1,2,方涵露1,2,李婧怡2,刘耀午2,莫淼2,3*,解婧1,2* |
|
|
(1. 复旦大学附属肿瘤医院中西医结合科, 肿瘤微创治疗中心, 上海 200032;
2. 复旦大学上海医学院肿瘤学系, 上海 200032;
3. 复旦大学附属肿瘤医院肿瘤预防部, 上海 200032
*通信作者) |
|
| 摘要: |
| 目的 根据国际癌症研究机构发布的2022年全球癌症统计报告，结合性别、年龄和人类发展指数（HDI）等，分析2022年全球及中国胰腺癌的发病和死亡情况。方法 全球185个国家和地区的胰腺癌数据来源于GLOBOCAN 2022数据库，HDI根据联合国开发计划署公布的《2022年人类发展报告》获取。将癌症数据按年龄、性别和HDI分层，描述全球及中国的胰腺癌流行情况。使用Pearson相关分析评估标化发病率（SIR）、标化死亡率（SMR）及死亡发病比（M/I）与HDI的相关性。结果 2022年全球胰腺癌总发病人数为51.10万，在各癌种中位列第12位，SIR（4.7/10万）位列第15位；全球胰腺癌总死亡人数为46.74万，在各癌种中位列第6位，SMR（4.2/10万）位列第9位。中国胰腺癌总发病人数为11.87万，在中国各癌种中位列第10位，占全球胰腺癌总发病人数的23.22%，SIR（4.4/10万）位列中国各癌种的第13位；中国胰腺癌总死亡人数为10.63万，在中国各癌种中位列第6位，占全球胰腺癌总死亡人数的22.74%，SMR（3.9/10万）位列中国各癌种的第8位。全球及中国的男性胰腺癌发病人数、死亡人数、SIR和SMR均高于女性。胰腺癌SIR和SMR均与HDI呈正相关（r=0.77、0.77，均P＜0.001），而M/I与HDI呈负相关（r=-0.43，P＜0.001）。全球及中国的胰腺癌发病人数、死亡人数、SIR和SMR随年龄增长呈上升趋势，从45～49岁开始迅速增长。结论 全球及中国胰腺癌疾病负担严重，胰腺癌的发病和死亡率随年龄增长呈上升趋势。男性的胰腺癌发病率和死亡率均高于女性。HDI与胰腺癌SIR和SMR呈正相关，而与M/I呈负相关。 |
| 关键词: 胰腺肿瘤 世界人口年龄标准化发病率 世界人口年龄标准化死亡率 死亡发病比 人类发展指数 |
| DOI：10.16781/j.CN31-2187/R.20240630 |
| 投稿时间：2024-09-05修订日期：2024-10-14 |
| 基金项目:国家自然科学基金面上项目（82074202）. |
|
| Incidence and mortality of pancreatic cancer in the world and China in 2022 |
| YI Lixia1,2,FANG Hanlu1,2,LI Jingyi2,LIU Yaowu2,MO Miao2,3*,XIE Jing1,2* |
(1. Department of Integrative Oncology, Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai 200032, China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China;
3. Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai 200032, China
*Corresponding authors) |
| Abstract: |
| Objective To analyze the incidence and mortality of pancreatic cancer in 2022 globally and in China based on the Global Cancer Statistics 2022 published by the International Agency for Research on Cancer, considering characteristics such as gender, age, and human development index (HDI). Methods Pancreatic cancer data from 185 countries and regions were sourced from the GLOBOCAN 2022 database, and HDI data were compiled based on the Human Development Report 2022 published by the United Nations Development Programme.Cancer data were stratified by age, gender, and HDI to describe the prevalence of pancreatic cancer globally and in China.Pearson correlation analysis was used to evaluate the correlation of standardized incidence rate (SIR), standardized mortality rate (SMR), and mortality-to-incidence ratio (M/I) with HDI. Results In 2022, the number of pancreatic cancer incident cases worldwide was 510 992, ranking 12th among all cancer incidents, with an SIR of 4.7 per 100 000 (ranking 15th).The number of pancreatic cancer deaths globally was 467 409, ranking 6th among all cancer deaths, with an SMR of 4.2 per 100 000 (ranking 9th).In China, the number of pancreatic cancer incident cases was 118 672 (ranking 10th among all cancer incidents), accounting for 23.22% of the global pancreatic cancer incidents, with an SIR of 4.4 per 100 000 (ranking13rd).The number of pancreatic cancer deaths in China was 106 295 (ranking 6th among all cancer deaths), accounting for 22.74% of the global pancreatic cancer deaths, with an SMR of 3.9 per 100 000 (ranking 8th).The incidence, mortality, SIR, and SMR in males were higher than those in females both globally and in China.SIR and SMR were positively correlated with HDI (r=0.77 and 0.77, both P＜0.001), while M/I was negatively correlated with HDI (r=-0.43, P＜0.001).The incidence, mortality, SIR and SMR of pancreatic cancer showed an increasing trend with age, and rapidly increased from 45-49 years old. Conclusion The disease burden of pancreatic cancer is serious globally and in China.The incidence and mortality of pancreatic cancer show an upward trend with age, and they are higher in males than in females.HDI is positively correlated with SIR and SMR of pancreatic cancer, while negatively correlated with M/I. |
| Key words: pancreatic neoplasms age-standardized incidence rate by world standard population age-standardized mortality rate by world standard population mortality-to-incidence ratio human development index |
